Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60076658%3A12310%2F19%3A43899768" target="_blank" >RIV/60076658:12310/19:43899768 - isvavai.cz</a>
Result on the web
<a href="https://www.sciencedirect.com/science/article/abs/pii/S0093775419301290?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S0093775419301290?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1053/j.seminoncol.2019.10.004" target="_blank" >10.1053/j.seminoncol.2019.10.004</a>
Alternative languages
Result language
angličtina
Original language name
Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity
Original language description
There is no doubt that immunotherapy lies in the spotlight of current cancer research and clinical trials. However, there are still limitations in the treatment response in certain types of tumors largely due to the presence of the complex network of immunomodulatory and immunosuppressive pathways. These limitations are not likely to be overcome by current immunotherapeutic options, which often target isolated steps in immune pathways preferentially involved in adaptive immunity. Recently, we have developed an innovative anti-cancer immunotherapeutic strategy that initially elicits a strong innate immune response with subsequent activation of adaptive immunity in mouse models. Robust primary innate immune response against tumor cells is induced by toll-like receptor ligands and anti-CD40 agonistic antibodies combined with the phagocytosis-stimulating ligand mannan, anchored to a tumor cell membrane by biocompatible anchor for membrane. This immunotherapeutic approach results in a dramatic therapeutic response in large established murine subcutaneous tumors including melanoma, sarcoma, pancreatic adenocarcinoma, and pheochromocytoma. Additionally, eradication of metastases and/or long-lasting resistance to subsequent re-challenge with tumor cells was also accomplished. Current and future advantages of this immunotherapeutic approach and its possible combinations with other available therapies are discussed in this review. Published by Elsevier Inc.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Seminars in Oncology
ISSN
0093-7754
e-ISSN
—
Volume of the periodical
46
Issue of the periodical within the volume
4-5
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
385-392
UT code for WoS article
000503326100013
EID of the result in the Scopus database
2-s2.0-85075328858